We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+23.97%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$71.6M
AUM Growth
-$14.6M
Cap. Flow
-$22.9M
Cap. Flow %
-31.94%
Top 10 Hldgs %
72.06%
Holding
37
New
3
Increased
6
Reduced
14
Closed
9

Top Buys

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$1.81M
2
CDTX
Cidara Therapeutics
CDTX
+$1.29M
3
TSHA icon
Taysha Gene Therapies
TSHA
+$1.06M
4
AKRO
Akero Therapeutics
AKRO
+$898K
5
TERN
Terns Pharmaceuticals
TERN
+$432K

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$5.28M
2
ELVN icon
Enliven Therapeutics
ELVN
+$5.22M
3
TRML
Tourmaline Bio
TRML
+$2.32M
4
MRK icon
Merck
MRK
+$2.06M
5
EWTX icon
Edgewise Therapeutics
EWTX
+$1.88M

Sector Composition

Rank Sector Weight
1 Healthcare 99.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RAPP
26
Rapport Therapeutics
RAPP
$1.95B
$227K 0.32%
20,000
+3,600
+22% +$38.2K
ARTV
27
Artiva Biotherapeutics
ARTV
$523M
$68.6K 0.1%
45,456
– –
NUVB.WS
28
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$24.5K 0.03%
90,832
– –
ELVN icon
29
Enliven Therapeutics
ELVN
$4.15B
– –
-265,269
Closed -$5.22M
EWTX icon
30
Edgewise Therapeutics
EWTX
$4.13B
– –
-85,454
Closed -$1.88M
FBRX icon
31
Forte Biosciences
FBRX
$1.57B
– –
-18,469
Closed -$143K
GILD icon
32
Gilead Sciences
GILD
$163B
– –
-9,298
Closed -$1.04M
MREO
33
Mereo BioPharma
MREO
$50.4M
– –
-791,815
Closed -$1.78M
MRK icon
34
Merck
MRK
$316B
– –
-22,994
Closed -$2.06M
RCKT icon
35
Rocket Pharmaceuticals
RCKT
$372M
– –
-83,350
Closed -$556K
VERV
36
DELISTED
Verve Therapeutics
VERV
– –
-162,724
Closed -$744K
1
2

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q2 2025 Portfolio in Review

As of Q2 2025, Acuta Capital Partners held 37 positions worth $71.6M, down 17% from $86.2M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Acuta Capital Partners withdrew a net $22.9M in Q2 2025, closing 9 positions and reducing 14 holdings. Its most notable exit was Enliven Therapeutics, an estimated $5.22M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

Against the trend, Acuta Capital Partners opened a new position in Taysha Gene Therapies worth $1.12M.

  • Acuta Capital Partners's largest Q2 2025 buy was Taysha Gene Therapies: 485,669 shares worth $1.12M.
  • Acuta Capital Partners added most to Jazz Pharmaceuticals in Q2 2025, an estimated $1.81M increase.
  • Acuta Capital Partners's biggest Q2 2025 reduction was Insmed, cutting an estimated $5.28M.
  • Acuta Capital Partners fully exited Enliven Therapeutics in Q2 2025, selling an estimated $5.22M.
  • Acuta Capital Partners's ten largest holdings make up 72% of its $71.6M portfolio in Q2 2025.
  • Acuta Capital Partners opened 3 new positions and closed 9 in Q2 2025.
  • Acuta Capital Partners's portfolio value fell 17% quarter-over-quarter to $71.6M.

Based on Acuta Capital Partners's 13F filing for Q2 2025, filed 14 Aug 2025.